{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:58:04Z","timestamp":1763755084434,"version":"3.45.0"},"reference-count":52,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2007,12,1]]},"DOI":"10.1188\/07.cjon.831-840","type":"journal-article","created":{"date-parts":[[2007,12,13]],"date-time":"2007-12-13T08:25:48Z","timestamp":1197534348000},"page":"831-840","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Updates and Nursing Considerations for Patients With Multiple Myeloma"],"prefix":"10.1188","volume":"11","author":[{"given":"Beth","family":"Faiman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,12,6]]},"reference":[{"key":"E00001","unstructured":"American Cancer Society. (2007). Cancer facts and figures<\/i>, 2007. Atlanta, GA: Author."},{"key":"E00002","unstructured":"Anagnostopoulos, A., Dimopoulos, M.A., Spencer, A., Attal, M., Prince, M., Harousseau, J.L., et al. (2007). A randomized phase 3 trial of oral lenalidomide and dexamethasone versus placebo and dexamethasone in patients with relapsed or refractory multiple myeloma. Final analysis of MM010 study [Abstract PO-661]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 171-172."},{"key":"E00003","unstructured":"Berenson, J.R., Lichtenstein, A., Porter, L., Dimopolous, M.A., Bordoni, R., George, S., et al. (1998). Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal of Clinical Oncology<\/i>, 16<\/b>, 593-602."},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Brown, L.M., Linet, M.S., Greenberg, R.S., Silverman, D.T., Hayes, R.B., Swanson, G.M., et al. (1999). Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer<\/i>, 85<\/b>, 2385-2390.","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2385::AID-CNCR13>3.0.CO;2-A"},{"key":"E00005","unstructured":"Celgene Corporation. (2007). Thalomid\u00ae [Package insert]. Retrieved July 17, 2007, from http:\/\/www.thalomid.com\/pdf\/Thalomid_Pl.pdf<\/a>"},{"key":"E00006","unstructured":"Chanan-Khan, A.A., Padmanabhan, S., Miller, K.C., Musiel, L., Yu, J., Bernstein, Z.P., et al. (2006). Final results of a phase II study of bortezomib (Velcade) in combination with liposomal doxorubicin (Doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma [Abstract 3539]. Blood, 108.<\/i> Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3539 http:\/\/www.abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3539<\/a>"},{"key":"E00007","unstructured":"Chanan-Khan, A.A., Weber, D., Dimopoulos, M., Chen, C., Niesvizky, R., Wang, M., et al. (2006). Lenalidomide (L) in combination with dexamethasone (D) improves survival and TTP in elderly patients (pts) with relapsed or refractory (rel\/ref) multiple myeloma (MM) [Abstract 3551]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3551 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3551<\/a>"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Colson, K., Doss, D.S., Swift, R., Tariman, J., & Thomas, T.E. (2004). Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: Nursing implications. Clinical Journal of Oncology Nursing<\/i>, 8<\/b>, 473-480.","DOI":"10.1188\/04.CJON.473-480"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., et al. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood<\/i>, 98<\/b>, 210-216.","DOI":"10.1182\/blood.V98.1.210"},{"key":"E00010","unstructured":"Dispenzieri, A., Zhang, L., Fonseca, R., Vesole, D.H., & Greipp, P.R. (2006). Single agent bortezomib is associated with a high response rate in patients with high risk myeloma. A phase II study from the Eastern Cooperative Oncology Group (E2A02) [Abstract 3527]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3527 http:\/\/www.abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3527<\/a>"},{"key":"E00011","doi-asserted-by":"crossref","unstructured":"Doss, D. (2006). Advances in oral therapy in the treatment of myeloma. Clinical Journal of Oncology Nursing<\/i>, 10<\/b>, 514-520.","DOI":"10.1188\/06.CJON.514-520"},{"key":"E00012","unstructured":"Durie, B.G., & Salmon, S.E. (1975). A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer<\/i>, 36<\/b>, 842-854."},{"key":"E00013","doi-asserted-by":"crossref","unstructured":"Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., et al. (2005). International staging system for multiple myeloma. Journal of Clinical Oncology<\/i>, 23<\/b>, 3412-3420.","DOI":"10.1200\/JCO.2005.04.242"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Harousseau, J.L., Nagler, A., Sonneveld, P., Blade, J., Hajek, R., Spencer, A., et al. (2007). Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone [Abstract 8002]. Journal of Clinical Oncology<\/i>, 25<\/b>(18 Suppl.).","DOI":"10.1200\/jco.2007.25.18_suppl.8002"},{"key":"E00015","unstructured":"Hussein, M. (1994). Multiple myeloma: An overview of diagnosis and management. Cleveland Clinic Journal of Medicine<\/i>, 61<\/b>, 285-298."},{"key":"E00016","doi-asserted-by":"crossref","unstructured":"Jagannath, S., Durie, B.G., Wolf, J.L., Camacho, E.S., Irwin, D., Lutzky, J., et al. (2006). Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma [Abstract 796]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/796 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/796<\/a>","DOI":"10.1182\/blood.V108.11.796.796"},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., et al. (2006). Cancer statistics, 2006. CA: A Cancer Journal for Clinicians<\/i>, 56<\/b>, 106-130.","DOI":"10.3322\/canjclin.56.2.106"},{"key":"E00018","unstructured":"Knop, S., Gerecke, C., Topp, M.S., Frohnert, S., Liebisch, P., Hess, G., et al. (2007). RAD (Revlimid, Adriamycin, Dex) is a new treatment regimen for relapsed multiple myeloma [Abstract PO-658]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 170-171."},{"key":"E00019","doi-asserted-by":"crossref","unstructured":"Lacy, M., Gertz, M., Dispenzieri, A., Hayman, S., Geyer, S., Zeldenrust, S., et al. (2006). Lenalidomide plus dexamethasone (Rev\/Dex) in newly diagnosed myeloma: Response to therapy, time to progression, and survival [Abstract 798]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/798 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/798<\/a>","DOI":"10.1182\/blood.V108.11.798.798"},{"key":"E00020","unstructured":"Lonial, S., Knight, R., Dimopoulos, M., Chanan-Khan, A., San-Miguel, J., Facon, T., et al. (2007). Effect of len\/dex in MM in different age groups [Abstract PO-663]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 172-173."},{"key":"E00021","unstructured":"Malpas, J.S., Bergsagel, D.E., Kyle, R., & Anderson, K. (2004). Myeloma biology and management<\/i> (3rd ed.). Philadelphia: Saunders."},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Mehrotra, B., & Ruggiero, S. (2006). Bisphosphonate complications including osteonecrosis of the jaw. Hematology 2006: American Society of Hematology education program book<\/i> (pp. 356-360). Retrieved March 12, 2007, from http:\/\/asheducationbook.hematologylibrary.org\/cgi\/content\/full\/2006\/1\/356<\/a>","DOI":"10.1182\/asheducation-2006.1.356"},{"key":"E00023","unstructured":"Millennium Pharmaceuticals, Inc. (2007). Velcade\u00ae [Package insert]. Retrieved July 17, 2007, from http:\/\/www.mlnm.com\/products\/velcade\/full_prescrib_velcade.pdf<\/a>"},{"key":"E00024","unstructured":"Mitchell, S., Beck, S., Hood, L., Moore, K., & Tanner, E. (2005). Fatigue: What interventions are effective in preventing and treating fatigue during and following cancer and its treatment? Retrieved November 15, 2007, from http:\/\/www.ons.org\/outcomes\/volume1\/fatigue\/detpep_fatigue.shtml<\/a>"},{"key":"E00025","unstructured":"Nagler, A., Hajek, R., Sonneveld, P., Spencer, A., Blade, J., Robak, T., et al. (2007). Doxil + Velcade in previously treated myeloma w\/prior SCT [Abstract PO-625]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 161."},{"key":"E00026","unstructured":"National Comprehensive Cancer Network. (2007). NCCN clinical practice guidelines in oncology: Multiple myeloma<\/i> [Version 3. 2007]. Retrieved February 23, 2007, from http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf<\/a>"},{"key":"E00027","unstructured":"Niesvizky, R., Jayabalan, D., Zafar, F., Christos, P., Pearse, R., Jalbrzikowski, J.B., et al. (2007). BiRD (Biaxin\u00ae\/Revlimid\u00ae\/dexamethasone) in myeloma (MM) [Abstract PO-714]. Haematologica\/The Hematology Journal<\/i>, 92<\/b>(Suppl. 2), 178."},{"key":"E00028","doi-asserted-by":"crossref","unstructured":"Orlowski, R.Z., Peterson, B.L., Sanford, B., Chanan-Khan, A.A., Zehngebot, L.M., Watson, P.R., et al. (2006). Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301 [Abstract 797]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/797 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/797<\/a>","DOI":"10.1182\/blood.V108.11.797.797"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Orlowski, R.Z., Zhuang, S.H., Parekh, T., Xiu, L., Harousseau, J.L., & DOXIL-MMY-3001 Study Investigators. (2006). The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed\/refractory multiple myeloma compared with bortezomib alone: Results from a planned interim analysis of a randomized phase I II study [Abstract 404]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/404 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/404<\/a>","DOI":"10.1182\/blood.V108.11.404.404"},{"key":"E00030","doi-asserted-by":"crossref","unstructured":"Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., et al. (2006). Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet<\/i>, 367<\/b>, 825-831.","DOI":"10.1016\/S0140-6736(06)68338-4"},{"key":"E00031","unstructured":"Palumbo, A., Dimopoulos, M., San Miguel, J., Harousseau, J-L., Attal, M., Hussein, M., et al. (2007). VTE management recommendations for len\/dex in MM [Abstract PO-1121]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 217."},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"Palumbo, A., Falco, P., Falcone, A., Corradini, P., Di Raimondo, F., Giuliani, N., et al. (2006). Oral Revlimid\u00ae plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter phase I\/II study [Abstract 800]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/800 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/800<\/a>","DOI":"10.1182\/blood.V108.11.800.800"},{"key":"E00033","unstructured":"Pelliniemi, T.T., Irjala, K., Mattila, K., Pulkki, K., Rajamaki, A., Tienhaara, A., et al. (1995). Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood<\/i>, 85<\/b>, 765-771."},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Pilarski, L.M., Mant, M.J., & Ruether, B.A. (1985). Pre B-cells in peripheral blood of multiple myeloma patients. Blood<\/i>, 66<\/b>, 416-422.","DOI":"10.1182\/blood.V66.2.416.416"},{"key":"E00035","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Hussein, M., Catalano, J., Jedrzejcak, W., Sirkovich, S., Olesnyckyj, M., et al. (2006). A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma [Abstract 795]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/795 http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/795<\/a>","DOI":"10.1182\/blood.V108.11.795.795"},{"key":"E00036","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Jacobus, S., Callander, N., Fonseca, R., Vesole, D., Williams, M., et al. (2007). Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group [Abstract LBA8025]. Journal of Clinical Oncology<\/i>, 25<\/b>(18, Suppl.).","DOI":"10.1200\/jco.2007.25.18_suppl.lba8025"},{"key":"E00037","unstructured":"Reece, D.E., Masih-Khan, E., Chen, C., Wang, L., Dean, S., Kukreti, V., et al. (2006). Use of lenalidomide (Revlimid\u00ae) +\/- corticosteroids in relapsed\/refractory multiple myeloma patients with elevated baseline serum creatinine levels [Abstract 3548]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3548 http:\/\/www.abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/3548<\/a>"},{"key":"E00038","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Jagannath, S., Avigan, D.E., Alsina, M., Schlossman, R.L., Mazumder, A., et al. (2006). Lenalidomide plus bortezomib (Rev-Vel) in relapsed and\/or refractory multiple myeloma (MM): Final results of a multicenter phase 1 trial [Abstract 405]. Blood<\/i>, 108<\/b>. Retrieved March 12, 2007, from http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/405 http:\/\/www.abstracts.hematologylibrary.org\/cgi\/content\/abstract\/108\/11\/405<\/a>","DOI":"10.1182\/blood.V108.11.405.405"},{"key":"E00039","unstructured":"Richardson, P.G., Jagannath, S., Raje, N., Ghobrial, I., Schlossman, R.L., Mazumder, A., et al. (2007). Phase 2 study of Rev\/Vel\/Dex in relapsed\/refractory MM [Abstract PO-660]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 171."},{"key":"E00040","unstructured":"San-Miguel, J.F., Hajek, R., Nagler, A., Sonneveld, P., Spencer, A., Blade, J., et al. (2007). Doxil\u00ae + Velcade\u00ae in previously treated \u226565Y myeloma pts [Abstract PO-620]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 159."},{"key":"E00041","unstructured":"Sheridan, C.A., & Serrano, M. (2000). Multiple myeloma. In C.H. Yarbro, M.H. Frogge, M. Goodman, & S.L. Groenwald (Eds.), Cancer nursing: Principles and practice<\/i> (5th ed., pp. 1354-1370). Sudbury, MA: Jones and Bartlett."},{"key":"E00042","doi-asserted-by":"crossref","unstructured":"Solly, S. (1844). Remarks on the pathology of mollities ossium with cases. Medico-Chirurgical Transactions of London<\/i>, 27<\/b>, 435-461.","DOI":"10.1177\/095952874402700129"},{"key":"E00043","unstructured":"Sonneveld, P., Dimopoulos, M., San Miguel, J., Harousseau, J-L., Attal, M., Hussein, M., et al. (2007). Recommended management of cytopenia for len\/dex in MM [Abstract PO-1123]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 217-218."},{"key":"E00044","doi-asserted-by":"crossref","unstructured":"Sonneveld, P., Hajek, R., Nagler, A., Spencer, A., Blade, J., Robak, T., et al. (2007). Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed\/refractory multiple myeloma (RRMM) [Abstract 8023]. Journal of Clinical Oncology<\/i>, 25<\/b>(18 Suppl.).","DOI":"10.1200\/jco.2007.25.18_suppl.8023"},{"key":"E00045","unstructured":"Spencer, A., Hajek, R., Nagler, A., Sonneveld, P., Blade, J., Robak, T., et al. (2007). Doxil\u00ae + Velcade\u00ae in previously treated high risk myeloma [Abstract PO-629]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 162."},{"key":"E00046","unstructured":"Tipton, J., McDaniel, R., Barbour, L., Johnston, M.P, LeRoy, P., Kayne, M., et al. (2005). Nausea and vomiting interventions: What interventions are effective in preventing and treating chemotherapy-induced nausea and vomiting? Retrieved November 15, 2007, from http:\/\/www.ons.org\/outcomes\/volume1\/nausea\/detpep_nausea.shtml<\/a>"},{"key":"E00047","doi-asserted-by":"crossref","unstructured":"Tricot, G., Sawyer, J.R., Jagannath, S., Desikan, K.R., Siegal, D., Nauke, S., et al. (1997). Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. Journal of Clinical Oncology<\/i>, 15<\/b>, 2659-2666.","DOI":"10.1200\/JCO.1997.15.7.2659"},{"key":"E00048","unstructured":"Vescio, R.A., & Berenson, J.R. (2000). Multiple myeloma, macroglobulinemia and heavy chain disease. In C.M. Haskell (Ed.), Cancer treatment<\/i> (5th ed., pp. 1503-1539). Philadelphia: Saunders."},{"key":"E00049","unstructured":"Visovsky, C., Collins, M.L., Hart, C., Abbott, L., & Aschenbrenner, J.A. (2005). Peripheral neuropathy: What interventions are used to prevent or reduce the effects of peripheral neuropathy for people with cancer? Retrieved November 15, 2007, from http:\/\/www.ons.org\/outcomes\/volume2\/peripheral.shtml<\/a>"},{"key":"E00050","unstructured":"Wang, M., Knight, R., Dimopoulos, M., Siegel, D., Rajkumar, S.R., Facon, T., et al. (2007). Effect of len\/dex in MM despite that resistance [Abstract PO-662]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 172."},{"key":"E00051","unstructured":"Weber, D.M. (2007). Lenalidomide for the treatment of relapsed or refractory multiple myeloma [Abstract S4.2]. Haematologica<\/i>, 92<\/b>(Suppl. 2), 22-24."},{"key":"E00052","doi-asserted-by":"crossref","unstructured":"Zonder, J.A. (2006). Thrombotic complications of myeloma therapy. Hematology 2006: American Society of Hematology education program book<\/i> (pp. 348-355). Retrieved March 12, 2007, from http:\/\/www.asheducationbook.hematologylibrary.org\/cgi\/content\/full\/2006\/1\/348<\/a>","DOI":"10.1182\/asheducation-2006.1.348"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/A60314NT77102781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:55Z","timestamp":1763754655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/11\/6\/clinical-updates-and-nursing-considerations-patients-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12,1]]}},"alternative-id":["A60314NT77102781"],"URL":"https:\/\/doi.org\/10.1188\/07.cjon.831-840","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2007,12,1]]}}}